Mounjaro Enters India
Eli Lilly, the American pharmaceutical giant, announced the launch of its diabetes and weight-loss treatment, Mounjaro (tirzepatide), in India. With approval from India’s Central Drugs Standard Control Organization (CDSCO), the company is now offering Mounjaro in single-dose vials for use in India.
What is Mounjaro
Mounjaro is a weekly injectable medication designed for managing type 2 diabetes and supporting weight loss.
The treatment typically begins with a lower dose, and over time, healthcare providers may gradually increase the dosage based on how the patient responds to the medication.
Doctors will closely monitor the patient’s progress and make any necessary adjustments to the dosage.
The frequency of doses required may differ from person to person, depending on individual needs and responses to the treatment.
Obesity Statistics in India. What the Numbers Are Telling Us?
India is grappling with a growing health crisis, with approximately 101 million people living with diabetes, and nearly half of them not receiving adequate treatment for glycemic control. The rising obesity rates in the country contribute significantly to this issue.
According to the 2024 Lancet study, India has an alarming number of people affected by obesity, with at least 44 million women and 26 million men over 20 years old clinically obese.
The World Obesity Federation Atlas forecasts that by 2035, 11% of Indian adults will be obese, which poses a significant challenge for the healthcare system.
The World Health Organization (WHO) has highlighted that obesity is a major contributor to several chronic diseases. It is responsible for 44% of all diabetes cases, 23% of ischemic heart diseases, and 7-41% of cancer cases globally. In India, obesity and its associated health risks, such as hypertension and heart disease, continue to rise.
To combat this growing problem, the introduction of weight-loss drugs like Mounjaro offers a promising solution when combined with sustainable lifestyle changes.
The anti-obesity drug market in India has already seen rapid growth, expanding from ₹137 crore in 2020 to an estimated ₹535 crore by 2024. This surge in demand reflects the increasing prevalence of obesity and diabetes, and experts predict the global market for GLP-1 drugs could reach $100 billion by 2030.
However, individuals must consult healthcare providers to assess whether such treatments are suitable for their specific health needs.
With obesity continuing to rise and India having the second-highest number of type 2 diabetes cases globally, addressing these issues is crucial for improving public health.
Existing Weight loss drug in India
Novo Nordisk’s oral semaglutide tablet, Rybelsus, which was launched in India in January 2022, has quickly become the market leader in the anti-obesity drug segment, capturing nearly 65% of the market.
This includes other weight-loss drugs like dulaglutide, orlistat, and liraglutide.
Although Rybelsus has gained significant traction, it only offers about 50% of the efficacy of its injectable counterpart. While it contains the same active ingredient, semaglutide, as Wegovy and Ozempic, it is considered less effective than these blockbuster injectable options.
How weight loss drugs works?
Weight loss drugs like Mounjaro (tirzepatide) have gained attention for their ability to help manage blood sugar levels, curb hunger, and slow digestion, making individuals feel full for longer periods.
Mounjaro works by activating two hormone receptors—GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), both of which play a key role in regulating blood sugar and appetite.
GLP-1 is a naturally occurring hormone that plays a key role in regulating blood sugar levels, making it vital for managing diabetes. However, it is quickly broken down in the body, which makes it challenging to use as a medication.
In the 1980s, researchers discovered that the venom of the Gila monster contained a more durable GLP-1-like substance. This breakthrough led to the creation of Semaglutide by Novo Nordisk. Initially developed to improve blood sugar control in diabetics, Semaglutide had an unexpected side effect—it significantly reduced appetite and cravings, leading to substantial weight loss.
This discovery opened up new possibilities for using the drug in obesity treatment. Over time, further studies have revealed that Semaglutide not only helps with blood sugar management but also offers significant benefits for weight control, making it a groundbreaking option for those struggling with both diabetes and obesity.
In clinical trials, adults who took Mounjaro alongside a balanced diet and exercise regimen experienced significant weight loss. Those on the highest dose (15 mg) lost an average of 21.8 kg, while those on the lower dose (5 mg) lost around 15.4 kg over 72 weeks.
You know about Ozempic. But do you know about Mounjaro (tirzepatide), a drug for diabetes and weight loss that was launched in India this week? All the basics about this new blockbuster drug in my video–> pic.twitter.com/YN1nBrApFW
— Dr Nandita Iyer (@saffrontrail) March 23, 2025
Benefits & side effects
Mounjaro offers significant benefits, including effective blood sugar management and notable weight loss.
However, like any medication, it comes with potential side effects, such as nausea, diarrhea, loss of appetite, vomiting, constipation, and stomach discomfort. Although rare, long-term risks may include digestive issues, kidney complications, gallbladder problems, and pancreatitis.
Given these factors, it is essential for individuals considering Mounjaro to consult with healthcare professionals to carefully assess the drug’s benefits and risks, ensuring it’s a suitable option based on their health requirements and financial circumstances.
Cost of Weight Loss Drugs in India
The drug has already gained significant global recognition, generating over $20 billion in sales since its initial release in the United States in 2022.
While Mounjaro provides a range of health benefits, including weight reduction, better blood sugar control, and a reduced risk of obesity-related illnesses, the cost can be a significant concern in India, especially for long-term use
Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India at significantly lower prices compared to the United States.
The drug, which is administered once a week, is priced at Rs 3,500 for the 2.5 mg vial and Rs 4,375 for the 5 mg vial. With a monthly dose typically ranging from 2.5 mg to 5 mg, patients in India will pay between Rs 14,000 and Rs 17,500 for a month’s supply.
This is a far cry from the cost in the US, where the same treatment can run around $1,000 (approximately Rs 86,000-1 lakh) per month.
A 2.5 mg vial of Mounjaro in India is priced at about Rs 3,500 ($40.5), the equivalent dosage in the US costs around $568, which is roughly 14 times more.
This competitive pricing in India, made possible through the approval by the Central Drugs Standard Control Organization (CDSCO), offers Mounjaro at a fraction of the cost found in the US market.
Mounjaro is available in a range of doses, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL injection. As for the cost in India, a patient using the 2.5 mg dose will spend approximately Rs 14,000 monthly, totalling Rs 168,000 annually.
However, Eli Lilly’s pricing strategy reflects its intention to make the drug more accessible to the Indian market, where there are approximately 101 million people living with diabetes. Even if just a small percentage of these patients choose Mounjaro, it could generate significant sales for the company. Despite the lower price point in India, Mounjaro’s cost will still be beyond the reach of many due to its relatively high price compared to local incomes.
Looking ahead, Eli Lilly’s first-mover advantage in India could face challenges as its competitor, semaglutide (brand name Ozempic), is expected to become available as a generic drug by 2026. This could lead to steep price reductions—potentially as much as 95% lower than Mounjaro’s current cost—further increasing competition in the growing GLP-1 drug market.
Is Mounjaro still considered affordable in India?
In countries abroad, medications like Mounjaro are often covered by insurance policies. However, in India, where healthcare spending accounts for only about 1 to 1.5% of the total GDP, incorporating such expensive drugs could pose a significant challenge.
With a large population of type 2 diabetics—many of whom are also overweight or obese (approximately 80%)—the financial strain on the healthcare system could be substantial if these drugs were widely prescribed. If insurance companies began covering such treatments for obesity as well, the costs could quickly add up, creating a significant burden.
Despite the cost concerns, healthcare professionals emphasize that combining Mounjaro with a healthy diet and regular exercise can be an effective approach to managing type 2 diabetes and supporting weight loss. However, the affordability and accessibility of such treatments remain key challenges in India’s healthcare landscape.
How safe is Mounjaro?
Despite the growing excitement surrounding Mounjaro, there are still lingering questions about its safety, long-term effects, and accessibility.
While the drug has shown promising results, experts caution that it is not without risks. As with other GLP-1 receptor agonists, Mounjaro can cause side effects such as nausea, vomiting, diarrhea, and constipation.
Mounjaro is not suitable for people with type 1 diabetes or children under 18. Always consult your doctor before use.
Some patients have experienced more serious complications, including gallbladder issues, pancreatitis, and, in rare cases, potential thyroid tumors. Additionally, when used in combination with insulin or sulfonylureas, there is a risk of low blood sugar.
Their long-term effects on cardiovascular health, pancreatic function, and overall metabolism are still being studied.
Before starting Mounjaro, make sure to:
- Have your healthcare provider demonstrate how to properly use the medication, especially if it’s your first time.
- Discuss low blood sugar with your provider and learn how to manage it.
- If you take oral birth control, consult your healthcare provider beforehand. Mounjaro may reduce the effectiveness of birth control pills. Your doctor may recommend an alternative form of contraception for 4 weeks after you begin Mounjaro or after each dose increase.
Mounjaro is expected to become available through prescription and will be used under medical supervision. However, as with any new treatment, ongoing research will be essential to fully understand its benefits and potential risks over time.
Emerging weight loss medications. Upcoming drugs to watch
The patent for semaglutide, the key ingredient in Wegovy, is expected to expire in India by 2026, which could allow local pharmaceutical companies to produce generic versions of the drug, potentially making it more affordable.
Major Indian pharmaceutical companies like Sun Pharma, Cipla, Dr. Reddy’s, and Lupin are reportedly working on developing their own generic versions of these weight-loss medications.
Novo Nordisk has announced plans to launch its popular weight-loss drug, Wegovy, in India by 2026. The drug contains semaglutide, which is expected to lose its patent protection in India by that same year.
In recent years, Novo Nordisk has seen remarkable growth. In 2023, its share price surged by more than four times from where it stood five years earlier. This increase propelled the company to become Europe’s most valuable business, surpassing the GDP of its home country, Denmark. In the United States, its drug Ozempic has become a dominant player, with over 65% of all prescriptions in the US in 2022 being for this medication alone.
Wegovy and Eli Lilly’s Mounjaro both belong to the GLP-1 agonist class of treatments, which have gained widespread popularity due to their effectiveness in controlling blood sugar levels and promoting weight loss.
Sun Pharmaceutical, India’s largest drugmaker by revenue, is developing its own GLP-1 treatment for weight loss and type 2 diabetes.
Biocon is also working on its version of Wegovy, as Novo’s patent is set to expire next year.
Zydus Lifesciences is developing a generic version of semaglutide and plans to launch it in India after the patent expires.
Cipla, India’s third-largest drugmaker by sales, is producing a cheaper version of Wegovy and has expressed interest in collaborating with Eli Lilly to market Mounjaro in India.
Dr. Reddy’s has plans to launch generic versions of semaglutide in all markets once Novo’s patent expires.
Lupin is another Indian generic drugmaker looking to capitalize on the growing demand for obesity treatments with its own version of Wegovy.
Additionally, Natco Pharma, Mankind Pharma, and Aurobindo Pharma are reportedly developing more affordable versions of Novo’s Wegovy.
Surging demand for weight loss drugs
The demand for GLP-1 drugs, which help with weight loss and diabetes management, has seen a significant surge in recent years. Goldman Sachs predicts that the global market for these drugs will reach a staggering $100 billion by 2030.
In India, the situation is no different, as the country grapples with a rapidly growing obesity and diabetes crisis.
Celebrities Who Have Openly Discussed Using Weight Loss Drugs:
Elon Musk: The CEO of Tesla and SpaceX revealed using Ozempic to aid his weight loss. Source: New York Post – Elon Musk’s Weight Loss Drug
Wendy Williams: The TV host shared her experience with Wegovy, a GLP-1 drug, to manage her weight. Daily Mail – Wendy Williams Weight Loss
Kyle Richards: The Real Housewives star discussed using Ozempic to help with weight loss. Source: People – Kyle Richards Talks Weight Loss
Lala Kent: The Vanderpump Rules star openly talked about using Ozempic for weight loss.
Raquel Leviss: Also from Vanderpump Rules, Raquel Leviss discussed using Wegovy for weight loss. TMZ – Raquel Leviss Weight Loss
Are weight loss drugs more effective than yoga and exercise? Bill gates shares his view
In a recent podcast with Raj Shamani, Bill Gates emphasized the challenges of sustained behavior change in tackling obesity, noting that no country has successfully mastered it. While acknowledging the value of yoga and lifestyle interventions discussed by leaders like India’s Prime Minister, Gates pointed to medical innovation—specifically GLP-1 receptor agonists—as a promising tool for weight management.
He suggested that lasting solutions will likely involve a combination of scientific advances and lifestyle changes, though the latter remains difficult to achieve at scale.
View this post on Instagram
The Economic Impact of Weight Loss Drugs
The influence of GLP-1 drugs extends beyond healthcare into the economy. Retailers such as Walmart have reported a decline in grocery sales, particularly in categories like junk food.
This trend may soon affect other sectors, including alcohol, tobacco, and processed food industries, as people reduce their consumption of these products.
In response, some food manufacturers are already looking for ways to pivot and adapt to shifting consumer behaviors. As weight loss medications become more widespread, these industries may need to rethink their strategies to meet evolving demands.
Threat of Counterfeit Weight Loss Drugs
The soaring demand for GLP-1 drugs has unfortunately sparked a black market for counterfeit and unapproved versions, with some clinics and gyms offering prescriptions without proper regulation.
While India has been slow to adopt these treatments, it stands to gain valuable insights from global experiences, especially as patents expire and prices decrease.
How to Get Mounjaro in India
Mounjaro will be available in registered pharmacies throughout India, but it will require a valid prescription for purchase.
Eli Lilly has chosen not to collaborate with local distributors and will handle the drug’s distribution directly. To meet the anticipated demand, the company has ramped up production capacity.
Future Outlook
A wave of new weight-loss drugs is on the horizon, with Novo Nordisk speeding up the launch of Wegovy, while Indian companies are developing generics for Semaglutide.
Experts suggest that if these drugs are made affordable, they could significantly transform the management of obesity and diabetes in India.
However, despite the growing excitement, safety concerns and accessibility issues continue to be major challenges.
This article is intended for informational purposes only and is not a substitute for professional medical advice. The content has been gathered through online research and fact collection from reputable sources. Before purchasing any medication, whether online or in-person, it is essential to consult a qualified healthcare provider. This ensures that the treatment is suitable for your individual health needs and that it is safe for you to use, particularly in the case of weight loss medications. Always prioritize expert guidance before making any health-related decisions.